James Rubenstein: Clinical Trials

3 trials sponsored by James Rubenstein, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting, 1 completed. 3 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Recruiting 2, Completed 1
Phase 21Recruiting 1

Follow James Rubenstein: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
Tafasitamab, Lenalidomide - CNS Lymphoma, Primary Central Nervous System Lymphoma
Phase 1 / Phase 2RecruitingJames Rubenstein352022-06-082026-07-14
Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma
Hyperpolarized pyruvate (13C), Magnetic resonance imaging (MRI) - Primary CNS Lymphoma
Phase 1RecruitingJames Rubenstein262021-06-292026-07-14
Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma
Lenalidomide, Rituximab - Recurrent/Refractory CNS, Intraocular Lymphoma
Phase 1CompletedJames Rubenstein142012-12-172020-08-11

Conditions studied

Intraocular Lymphoma (1)  ·  Lymphoma (1)  ·  Recurrence (1)

Interventions

Lenalidomide (2)  ·  Magnetic Resonance Spectroscopy (1)  ·  Rituximab (1)  ·  tafasitamab (1)

Countries

United States (3)

Results publications

PMID 29986852

NIH funding

R01CA239462 (1)